A growing body of research, generated primarily from MRI-based studies, shows that migraine appears to occur, and possibly endure, due to the alteration of specific neural processes in the central nervous system. However, information is lacking on the molecular impact of these changes, especially on the endogenous opioid system during migraine headaches, and neuronavigation through these changes has never been done. This study aimed to investigate, using a novel 3D immersive and interactive neuronavigation (3D-IIN) approach, the endogenous µ-opioid transmission in the brain during a migraine headache attack in vivo. This is arguably one of the most central neuromechanisms associated with pain regulation, affecting multiple elements of the pain experience and analgesia. A 36 year-old female, who has been suffering with migraine for 10 years, was scanned in the typical headache (ictal) and nonheadache (interictal) migraine phases using Positron Emission Tomography (PET) with the selective radiotracer [ 11 C]carfentanil, which allowed us to measure µ-opioid receptor availability in the brain (non-displaceable binding potential -µOR BP ND ). The short-life radiotracer was produced by a cyclotron and chemical synthesis apparatus on campus located in close proximity to the imaging facility. Both PET scans, interictal and ictal, were scheduled during separate mid-late follicular phases of the patient's menstrual cycle. During the ictal PET session her spontaneous headache attack reached severe intensity levels; progressing to nausea and vomiting at the end of the scan session. There were reductions in µOR BP ND in the pain-modulatory regions of the endogenous µ-opioid system during the ictal phase, including the cingulate cortex, nucleus accumbens (NAcc), thalamus (Thal), and periaqueductal gray matter (PAG); indicating that µORs were already occupied by endogenous opioids released in response to the ongoing pain. To our knowledge, this is the first time that changes in µOR BP ND during a migraine headache attack have been neuronavigated using a novel 3D approach. This method allows for interactive research and educational exploration of a migraine attack in an actual patient's neuroimaging dataset.
Introduction
Migraine is a chronic trigeminal pain disorder that affects nearly 16% of women and 6% of men in the United States and worldwide [1] [2] [3] . Repetitive migraine headache attacks have an impact on a large part of the patient's existence, impairing quality of life and performance, costing billions of dollars in missed school/work days and healthcare utilization 4 . During the debilitating headache attacks, its sufferers have a marked increased sensitivity to noxious (hyperalgesia) and even nonnoxious stimuli (allodynia) 5 .
The µ-opioid neurotransmitter system is one of the principal endogenous pain modulatory mechanisms in our brain. It is involved in the regulation of experimental and clinical pain perception, as well as in the analgesic action of opioid drugs [6] [7] [8] [9] which have been associated with the chronification of migraine attacks 10 
Protocol
The study should be approved by the local Institutional Review Board, and by the Radioactive Drug Research Committee. The research subject gives written informed consent to participate in the study. The protocol is divided into three chronological steps:
1. MRI session 2. PET session during the ictal phase (headache) of migraine 3. PET session during the interictal phase (no headache) of migraine
The patient is responsible for filling out a headache diary, and for confirming with the research group the occurrence of a migraine attack on the day of imaging session. Both, interictal and ictal, PET scans should be scheduled during separate mid-late follicular phases of the patient (5 to 10 days after the first day of menstrual bleeding), which in this case was tracked and calculated in advance by a gynecologist with expertise in the field (Y.R.S.).
MRI Session
1. Preparing for the Experiment 1. Prior to preparing the subject for the scan, it is necessary to follow proper safety instructions due to the magnetic field of the MR scanner. All study personnel must be metal-free before entering the MR procedure room. 2. Provide a copy of the Informed Consent Form, previously signed by the research volunteer during initial screening, to the MR technologist.
2. Preparing the Subject for the Scan 1. On the day of the MRI, ask the research subject to fill out a MRI safety screening form. This form is required for any MRI taken at the University of Michigan -fMRI lab. The questionnaire reinforces that the subject is also metal-free and does not have a medical condition that requires careful and special consideration (e.g., metallic foreign fragments, implanted mechanical/electrical device). 2. Reassure that the participant understands the MR procedure, risks and benefits. 3. Deliver the completed screening form to the MR technologist who will be assisting in the procedure. Prior to confirming the scan at the University Hospital, contact the subject to verify in which phase of the menstrual cycle she will be on the day of the scan. It is recommended to perform a PET scan during mid-late follicular phase (5 to 10 days following menstrual bleeding onset). 2. Submit a request to the hospital to produce [ 2. Preparing the Subject for the Scan 1. When the participant arrives in the hospital, escort her to the PET suite for revalidation of diagnosis based on the International Classification of Headache Disorders. Prior to the scan, perform a urine drug test to confirm that the subject did not intake any substance that could interact with the tracer [ 11 C]carfentanil, followed by an urine pregnancy test. 2. Reaffirm that the participant understands the PET procedure, risks, and benefits. 3. Deliver a copy of the Informed Consent Form, previously signed by the research volunteer during the initial screening, to the Nuclear Medicine technologist. 4. Following the guidance of the Nuclear Medicine technologist, help the subject settle into the scanner. 5. Have the subject undergo 1 90 min PET scan using a Siemens HR+ scanner in 3D mode (reconstructed images have a full-width at half maximum (FWHM) resolution of ~5.5 mm-in-plane and 5.0 mm axially). 6. For each [ 11 C]carfentanil dose (555 MBq ≤ 0.03 μg/kg), administer fifty percent as a bolus with the remainder continuously infused over the course of the scan to achieve steady-state tracer levels approximately 35 min after tracer administration. 7. Interictal PET session. 8. Repeat Steps 2.2 -2.6 during non-headache phase.
PET Data Reconstruction
1. Reconstruct PET images using interactive algorithms into a 128 x 128 pixel matrix in a 28.8 cm diameter field of view (FOV). 2. Acquire 21 image frames and co-register to one another to correct for motion during the scan. 3. Obtain a 6 min transmission (68Ge source) scan prior to the PET scan for the purposes of attenuation correction. 4 . Convert the dynamic image data for each scan on a voxel-by-voxel basis into two sets of parametric images (10 -40 min):
1. Use a tracer transport measure (K1 ratio) for coregistration and normalization procedures; and 2. Use a receptor-related measure, BP ND , proportional to Bmax (receptor concentration) to divide by Kd (receptor affinity).
5. Estimate these measures by using the reference region-based Logan graphical analysis with the occipital cortex as the reference region 12 .
PET Data Analysis
NOTE: Anatomically standardize images into template space using Statistical Parametric Mapping (SPM8) software following the sequence below.
1. Co-register the MR scan and K1 scans. 1. Define MarsBaR (in standardized space for each of these regions, with the exception of the PAG. Generate the PAG ROI by placing a 3 mm sphere at coordinates: right: 4, -28, -6; and left: -2, -28, -6. This PAG location was previously shown to have diffusional and connectivity alterations in migraine patients as compared to healthy controls 13, 14 . NOTE: Test-retest studies with [ 11 C]carfentanil show reproducibility of BP ND measures of well less than 10%, with most cortical regions being 3 -5% 15 . The largest coefficients of variation (CoV = Std.Dev./Mean) are typically observed in the regions with the lowest binding, however, even in the cortical regions with lowest binding BP ND CoV's were ~0.5. Hence, percentage changes in ROI µOR BP ND between scans are only considered as significant when above 10%.
3D-Neuronavigation

Preparing for an 3D-IIN Experience
1. Organize the data provided in NIfTI volumetric data format as a stack of images with density and activation levels defined as 16 bit. 2. Wear active LCD shutter glasses to enable the time sequential stereoscopic 3D effect. The shutter glasses operate through the blocking of one eye while the image for the other eye is shown on screen. The process then repeats for the other eye. This shuttering effect occurs at 110 Hz.
Representative Results
The patient presented to the hospital with a right temporal and occipital pulsating headache, with intensity of 6 on a 0-10 pain scale. She was having her typical migraine headache, however without aura. It had initiated upon awakening 5 hr before the (ictal) PET session, and she managed to tolerate it without any abortive pharmacotherapy. To her knowledge, the headache was not evoked by any triggering factor (e.g., alcohol, sleep deprivation). No autonomic symptoms were reported, but photophobia and phonophobia were present. Following initiation of the ictal PET session the headache intensity escalated, reaching severe levels (9 on a 0-10 pain scale) 60 min into the study; progressing to nausea and vomiting at the end of the scan session. Decrease in µOR BP ND was noticed in the brain of the patient during the spontaneous migraine headache (ictal phase), as compared to the baseline (interictal phase) (Figure 2 ). There were patent reductions in µOR BP ND in the main painmatrix regions of the endogenous µ-opioid system, including the following thalamus nuclei: right lateral dorsal (11, -19 In the brainstem, the significant ictal reduction in µOR BP ND extended from the rostral to caudal periaqueductal gray matter (PAG) (right: 4, -28, -6: 15.1%; left: -2, -28, -6: 14.6%) (Figure 3) . However, the global hemispheric percentage changes in the µOR BP ND during the migraine attack were modest (right: 8.5%; left: 8.29%), indicating that the decreases in the µOR BP ND were specific to the pain-matrix structures in the brain. 
Discussion
In this case report, actual migraine headache neuroimaging data was explored for the first time, in a fully immersive virtual 3D reality, which demonstrated a decrease in µ-opioid receptor availability (µOR BP ND ). Reductions in µOR BP ND imply that there is a higher occupancy and/or a loss of µ-opioid receptors in the central nervous system. Acute reductions in µOR BP ND in pain-matrix regions during the ictal scan as compared to the interictal scan, are expected to occur as a consequence of the release of endogenous opioids interacting with µORs as a regulatory response to the ongoing pain, making less µORs accessible to the radiotracer.
The novelty of our ictal migraine neuroimaging study lies in the new 3D neuronavigation approach to investigate a patient's actual brain data in virtual reality. PET radiotracer technology was used to measure changes in µORs availability with [ 11 C]carfentanil. When examined during the headache event, the brains of migraineurs are usually scanned following an attack trigger (e.g., glyceryl trinitrate, photostimulation) 16, 17 , or under the technical demand of a specific evoked stimulus (e.g., pain, brush, light, and odor) [18] [19] [20] . All those studies corroborate the knowledge that the disorder is associated with cortical and subcortical hyperexcitability during the headache phase. However, such a plethora of stimuli in the neuroimaging protocols introduces multiple factors that cloud our understanding of the sole impact of an acute migraine attack on the central nervous system. From the few previous functional studies without the presence of exogenous stimulation, there is indication of increased regional cerebral flow in areas such as the cingulate cortex, hypothalamus, and brainstem 21 , which can persist even after acute therapy 22 . Hitherto, the neuroimaging technologies applied have not allowed for the molecular characterization of neurotransmitter/receptor processes involved in the migraine attack, such as the endogenous µ-opioid mechanism, one of most important analgesic resources in the brain. Moreover, our method allowed these processes to be explored using 3D neuronavigation in a virtual environment.
The descending pain modulatory system is a complex network that regulates pain processing to a great extent via μ-opioid receptors throughout the brain, including spinal to supra-spinal areas. These areas are known to be involved in endogenous anti-nociception, stress-induced analgesia, and in the action of opioid drugs commonly used for chronic pain and migraine treatment. In fact, the dural neurogenic vasodilation associated with migraine can be inhibited by morphine and subsequently reversed by the opioid antagonist naloxone, indicating that the effects of morphine on neurogenic inflammation are mediated specifically via activation of µ-opioid receptors 23 . Interestingly, the magnitude of endogenous opioid/µORs regional activations in humans is related to the individual's capacity to suppress sensory and affective elements of the pain experience 24 .
In our study, the brain regions that showed reductions in µ-opioid receptor availability during the ictal phase are responsible for both elements of the migraine headache experience and its modulation. They are the ACC, thalamus, basal ganglia (e.g., NAcc), hippocampus, and the PAG. In addition to sensitization due to abnormal trigeminal afferent traffic, one solid hypothesis for migraine pathophysiology is the dysfunction of the
